BRCA and CDK4/6: allies or antagonists?-efficacy of CDK4/6 inhibitors in HR+/HER2- breast cancer with germline BRCA1/2 mutations: a narrative review.

Transl Breast Cancer Res · 2026 · PMC12885774 · PMID 41675010

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

However, a meta-analysis of 30 studies involving over 35,000 patients showed a trend toward worse OS in patients with HR + /HER2 − early and advanced BC, harboring gBRCAm, an effect that was particularly pronounced among BRCA1 mutation carriers and observed across studies evaluating treatments such as PARPi, platinum-based chemotherapy, and CDK4/6i ( 11 , 18 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

&lt;i&gt;BRCA&lt;/i&gt; and CDK4/6: allies or antagonists?-efficacy of CDK4/6 inhibitors in HR&lt;sup&gt;+&lt;/sup&gt;/HER2&lt;sup&gt;-&lt;/sup&gt; breast cancer with germline &lt;i&gt;BRCA1/2&lt;/i&gt; mutations: a narrative review.

The sentences

<i>BRCA</i> and CDK4/6: allies or antagonists?-efficacy of CDK4/6 inhibitors in HR<sup>+</sup>/HER2<sup>-</sup> breast cancer with germline <i>BRCA1/2</i> mutations: a narrative review.